1. Changes in secondary outcome measures from baseline to 18 weeks (Gp, group; VAS, visual analogue scale).The beneficial effect of VSL#3 seems to be maintained throughout the 18 weeks study period, observed as continued significant improvement in stool frequency, stool mucus and well-being. .
Changes in secondary outcome measures from baseline to 18 weeks (Gp, group; VAS, visual analogue scale).The beneficial effect of VSL#3 seems to be maintained throughout the 18 weeks study period, observed as continued significant improvement in stool frequency, stool mucus and well-being.
Sarika Rohatgi et al. BMJ Open Gastroenterol 2015;2:e000018
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to